Latest Breaking News On - Institutional investors weigh in on apellis pharmaceuticals - Page 2 : comparemela.com

Brokerages Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Price Target at $78 60

Brokerages Set Apellis Pharmaceuticals, Inc (NASDAQ:APLS) Price Target at $78 60
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesCedric francoisPascal deschateletsSecurities exchange commissionProfund advisorsApellis pharmaceuticals incNews ratings for apellis pharmaceuticals dailyCharles schwab investment management incJefferies financial groupNeedham companyWynnefield capital incApellis pharmaceuticals stockAmerican investors coInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticalsInsider transactions at apellis pharmaceuticals

Apellis Pharmaceuticals (NASDAQ:APLS) Given New $57 00 Price Target at Wedbush

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Wedbush from $67.00 to $57.00 in a report issued on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 […]

Pascal deschateletsRaymond jamesMark jeffrey delongAnalyst recommendations for apellis pharmaceuticalsNews ratings for apellis pharmaceuticals dailyNeedham companyApellis pharmaceuticalsInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals company profileApellis pharmaceuticals stock performanceJefferies financial groupCovestor ltdStephens consultingGoldman sachs groupFinancial wealth managmentApellis pharmaceuticals inc

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2 3%

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 2 3%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Robertw bairdJames george chopasDavido watsonVanguard group incJefferies financial groupInsider activity at apellis pharmaceuticalsSierra summit advisorsInstitutional investors weigh in on apellis pharmaceuticalsApellis pharmaceuticals price performanceApellis pharmaceuticals incNeedham companyPricet rowe associates incNews ratings for apellis pharmaceuticals dailyEventide asset managementApellis pharmaceuticalsSecurities exchange commission

JPMorgan Chase & Co Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $79 00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lifted by JPMorgan Chase & Co. from $78.00 to $79.00 in a research note published on Wednesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. A number of other brokerages also recently issued reports on APLS. Robert W. […]

Robertw bairdJames george chopasAdamj townsendApellis pharmaceuticalsJefferies financial groupNeedham companyFirst horizon advisors incStephens consultingJpmorgan chase coAnalyst recommendations for apellis pharmaceuticalsUs bancorpCovestor ltdApellis pharmaceuticals incApellis pharmaceuticals stock downApellis pharmaceuticals company profileInstitutional investors weigh in on apellis pharmaceuticals

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel Sells $271,960 00 in Stock

Apellis Pharmaceuticals, Inc (NASDAQ:APLS) General Counsel Sells $271,960 00 in Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesDavido watsonRobertw bairdApellis pharmaceuticalsQuarter for apellis pharmaceuticalsWells fargo companyApellis pharmaceuticals incJennison associatesApellis pharmaceuticals price performanceAmerican investors coLisanti capital growthApellis pharmaceuticals company profileNeedham companyNews ratings for apellis pharmaceuticals dailyInstitutional investors weigh in on apellis pharmaceuticalsEnvestnet asset management inc